Realizing precision medicine based on companion diagnostics

The European Medicines Agency (EMA) has approved Truqap (active ingredient: capivasertib), an AKT inhibitor from AstraZeneca, for the treatment of locally advanced or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This approval is expected to accelerate the expansion of precision medicine based on companion diagnostics, which involves selecting patients for treatment based on genomic mutations. In particular, it targets patients with PIK3CA, AKT1, and PTEN gene mutations, providing a customized option for patients with refractory cancers who are resistant to existing treatments. This will further enhance the importance of biomarker testing in the breast cancer treatment market.

Therapeutic efficacy proven by Phase 3 clinical data

The basis for this approval is the CAPItello-291 Phase 3 clinical trial, which showed that the combination therapy of Truqap and fulvestrant demonstrated superior clinical benefits compared to the control group. In patients with confirmed gene mutations, the Truqap combination therapy achieved a median progression-free survival (PFS) of 7.3 months, reducing the risk of disease progression or death by 50% compared to the control group of 3.1 months (hazard ratio (HR) 0.50, p-value < 0.001). This is a very encouraging result for patients who are undergoing or have relapsed after first-line endocrine therapy. This solid clinical data is expected to be a strong foundation for Truqap to quickly establish itself as a standard of care in clinical practice in European countries.

Superior safety profile compared to competing drugs

The approval of Truqap offers significant advantages in terms of patient convenience compared to existing competing drugs, such as Novartis' PI3K inhibitor, Piqray (active ingredient: alpelisib). Piqray has a high incidence of hyperglycemia, a serious side effect caused by the blockade of the PI3K pathway, leading to frequent discontinuation of the drug by patients. In contrast, Truqap selectively inhibits AKT protein, reducing the incidence of hyperglycemia and significantly improving overall tolerability. The lower rate of drug discontinuation due to side effects will improve the patient's quality of life and enable continuous treatment, which will be an important factor in improving treatment success rates.

Market entry strategy and insurance coverage prospects

In order to successfully establish itself in the European market, it is essential to pass the health technology assessment (HTA) by each country's health authorities and obtain a reasonable price. Since Truqap is a targeted therapy for patients with gene mutations, it is likely to receive a higher recognition of its therapeutic value in price negotiations. However, in order to alleviate the financial burden of each government, it is necessary to present a customized reimbursement model linked to the speed of distribution of companion diagnostic devices. AstraZeneca is expected to adopt a strategy of quickly securing real-world data (RWD) to demonstrate clinical utility in order to lower the initial barriers to market entry and expand the scope of reimbursement.

AstraZeneca's portfolio expansion effect

The approval of Truqap is a significant milestone that strengthens AstraZeneca's oncology portfolio and provides a sustainable growth engine. In particular, it will maximize the synergy with existing representative breast cancer treatments, such as Enhertu and fulvestrant, and further solidify its dominance in the breast cancer treatment market. The fact that Truqap's global sales in 2025 reached $728 million, a 68% increase from the previous year, demonstrates this growth potential. If the expansion to other indications, such as triple-negative breast cancer (TNBC), is accelerated in the future, it is expected to grow into a blockbuster drug with annual sales exceeding $2 billion.